NeuroScientific Biopharmaceuticals appointment and FDA update

NeuroScientific Biopharmaceuticals Ltd (ASX: $NSB) has appointed Dr Tony Keating as Executive Director and filed a Pre-Investigation New Drug Application ('pre- IND') meeting request with the US Food and Drug Administration ('FDA') for EmtinB for the treatment of advanced glaucoma in adults. The meeting is expected to be held within 60 days.

NeuroScientific Chairman's Comments

We are extremely pleased that Dr Keating has stepped up to the role of Executive Director. Tony has a proven track record, having successfully led ResApp, which he co-founded, to being acquired by Pfizer for $180 million in 2022. Following the sale, Tony took on the role of Vice President at Pfizer, leading the integration of ResApp's business. Not only is Dr Keating extremely respected in the industry, but his international network is second to none. Importantly, discussing with the FDA the use of EmtinB to treat advanced glaucoma will provide clarity around our planned non-clinical and clinical glaucoma program, leading us closer to submission of an IND application and our first-in-human studies targeting glaucoma in the US. We are grateful for Tony transitioning into an executive role and providing a safe pair of hands as we progress towards submission. Lastly, the Board would like to thank Dougal for his time and wish him all the best in his future endeavors.

NeuroScientific Biopharmaceuticals FDA progress and executive appointment

NeuroScientific Biopharmaceuticals Ltd (ASX: $NSB) has made significant progress by appointing Dr Tony Keating as Executive Director and filing a Pre-Investigation New Drug Application ('pre- IND') meeting request with the US Food and Drug Administration ('FDA') for EmtinB for the treatment of advanced glaucoma in adults. The meeting is expected to be held within 60 days. Dr Keating's appointment brings a wealth of experience, having successfully led ResApp and played a key role in its acquisition by Pfizer. The company's discussions with the FDA regarding the use of EmtinB for advanced glaucoma treatment are a crucial step towards the submission of an IND application and the initiation of first-in-human studies targeting glaucoma in the US. NeuroScientific Biopharmaceuticals looks forward to the potential advancements in its glaucoma program and the contributions of Dr Keating in his new role as Executive Director.